Venomics AI Raises $2.7 Mn Pre-Seed to Turn Venom Into Drugs

Venomics AI, a biotech startup spun out of the Indian Institute of Science, has raised $2.7 million in its first institutional round. Speciale Invest and South Park Commons co-led the pre-seed, with Operators Studio participating, the Bengaluru-based company said in a press release.

That's a large pre-seed by Indian standards, and it lands in a niche most investors haven't touched: venom-derived drug discovery.

What does the money buy?

The proceeds will fund three things, per the company's press release:

• Expanding operations
• Growing its molecular dataset
• Strengthening its AI and laboratory screening capabilities

Sunagar and Vinay Prabhu co-founded Venomics AI in May 2026. The startup sits at the intersection of venom biology, molecular sequencing, AI and experimental screening — a stack it uses to discover and develop venom-derived therapeutic leads.

The core asset is the Venom Atlas, a platform that connects venom-derived molecular data with laboratory validation and drug discovery. The loop works like this: AI prioritises molecular candidates, functional screening in the lab tests those predictions, and the experimental results feed back into the next round of predictions and molecular design. Each cycle should, in theory, sharpen the next.

Venomics AI's bet is that India's venom biodiversity — plus its scientific and computational talent pool — can anchor a drug discovery platform aimed at global therapeutic development. Takeaway: it's a data-moat play built on a biological resource India has in abundance.

Where does the startup stand today?

The company isn't starting from zero. It has established the initial architecture of its platform, joined the NVIDIA Inception programme, and was selected among the top five finalists for the 2026 Indo-Boston Biotech Bridge Award.

Next on the agenda: building a multidisciplinary team spanning venom biology, computational science and drug discovery, while supporting validation and optimisation of promising molecules.

Who else is hunting in venom?

Venom-based drug discovery is a small but real field. Startups in the space are exploring bioactive peptides and proteins found in snake, scorpion and marine animal venoms to identify molecules with potential applications in pain management, neurological disorders, cardiovascular diseases and other therapeutic areas.

One comp: Snaayu Lifesciences, incubated at C-CAMP, is isolating and characterising novel analgesic compounds from cone snail venom.

The wider AI-driven drug discovery category is pulling capital too. Bengaluru-based Peptris Technologies raised Rs 70 crore in a Series A round in February 2026, co-led by IAN Alpha Fund and Speciale Invest. Peptris, like Venomics AI, pairs AI-driven molecular discovery with experimental validation to advance drug candidates.

Speciale Invest's presence on both cap tables signals a deliberate thesis: investors are backing Indian teams that combine computational screening with wet-lab validation rather than pure software plays. Whether venom-derived leads can clear the long, expensive bar of therapeutic development is the question the $2.7 million now has to answer.